RxDoctor Payments Data

Timothy Weimer, NP

Nurse Practitioner · Sewell, NJNPI 1447292495

Payments from drug & device makers

$3,009in general payments, 2019–2025

Across 87 payments — averaging $34.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Endo Pharmaceuticals Inc.$1K
  • Johnson & Johnson$278
  • Astellas Pharma US Inc$219
  • AstraZeneca$139
  • Progenics Pharmaceuticals, Inc.$125
  • Antares Pharma, Inc.$122
  • plus $935 from 22 others

What the payments were for

  • Consulting fees$1,15738%
  • Food & beverage$1,62354%
  • Education$2298%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,009 in reported general payments places this provider in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

See all nurse practitioner providers in New Jersey

Medicare billing

Part B allowed, 2024
$87,207
Medicare patients
296
Services billed
11,259

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron157$103,202
GemtesaVibegron37$44,379
XyostedTestosterone Enanthate57$43,663
Tamsulosin Hcl1,079$15,165
Testosterone69$9,902
Methenamine Hippurate116$8,909
Mirabegron ErMirabegron21$8,885
Tolterodine Tartrate ErTolterodine Tartrate95$8,810
Solifenacin Succinate190$8,312
Silodosin77$4,518
Fesoterodine Fumarate ErFesoterodine Fumarate38$3,900
Tadalafil129$3,877
NitrofurantoinNitrofurantoin Macrocrystal143$3,136
Desmopressin Acetate26$2,401
Testosterone Cypionate84$2,376

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$219$103,202157 claims
Antares Pharma, Inc.Xyosted$122$43,66357 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,138 nurse practitioner providers in New Jersey.

Other nurse practitioner in Sewell

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →